<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056638</url>
  </required_header>
  <id_info>
    <org_study_id>16-1686</org_study_id>
    <nct_id>NCT03056638</nct_id>
  </id_info>
  <brief_title>Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer</brief_title>
  <official_title>Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic body radiation therapy (SBRT) is a very precise form of radiation therapy that&#xD;
      allows the physician to deliver more radiation dose in a single session. Because of this, the&#xD;
      number of radiation sessions can be reduced from the typical 45-48 sessions, as in&#xD;
      conventional daily session radiation, to 5 sessions given every other day over a week and a&#xD;
      half. Giving the radiation at a higher dose during each treatment may be more effective in&#xD;
      killing the prostate cancer cells than the standard way of using external radiation therapy&#xD;
      where a small amount of radiation is given over many sessions.&#xD;
&#xD;
      Androgen Deprivation Therapy (ADT) or hormonal therapy is one of the methods to treat&#xD;
      intermediate risk prostate cancer. This therapy works by reducing the level of testosterone&#xD;
      and stopping them from affecting your cancer. The ADT used in this study is known as&#xD;
      Degarelix. Degarelix is an approved medication that reduces the body's production of&#xD;
      testosterone; this medication is usually given to all men with intermediate risk prostate&#xD;
      cancer getting external radiation.&#xD;
&#xD;
      This study is a randomized study to find out whether combining stereotactic (also known as&#xD;
      precision) radiation to the prostate cancer combined with a short course of Degarelix will&#xD;
      result in a greater likelihood of killing the cancer in the prostate compared to stereotactic&#xD;
      radiation therapy given alone. It has been shown that the combination of radiation with&#xD;
      medications that interfere with testosterone production and its effects makes prostate cancer&#xD;
      cells more sensitive to the radiation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients with intermediate risk disease will be randomized to ADT with SBRT versus SBRT alone. PSA and testosterone testing every 6 months, Biopsy 24-30 months after SBRT</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with a positive biopsy</measure>
    <time_frame>2 years</time_frame>
    <description>compare 2-year biopsy positivity rate of intermediate risk prostate cancer patients treated with SBRT + short course ADT versus SBRT alone.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Degarelix in conjunction with stereotactic body radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix monthly for 6 months SBRT 8 Gy x 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stereotactic body radiosurgery (SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT 8 Gy x 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix monthly for 6 months</description>
    <arm_group_label>Degarelix in conjunction with stereotactic body radiosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiosurgery (SBRT)</intervention_name>
    <description>SBRT 8 Gy x 5</description>
    <arm_group_label>Degarelix in conjunction with stereotactic body radiosurgery</arm_group_label>
    <arm_group_label>stereotactic body radiosurgery (SBRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven intermediate risk prostate cancer, which includes patients with any one&#xD;
             of the following variables:&#xD;
&#xD;
          -  Gleason 7 disease&#xD;
&#xD;
          -  PSA 10-20 ng/ml&#xD;
&#xD;
          -  Clinical T2b-T2c disease Note: Patients who only have radiographic evidence of T3&#xD;
             disease (i.e. extracapsular extension, or seminal vesical invasion radiographically)&#xD;
             will not be excluded.&#xD;
&#xD;
          -  Serum testosterone ≥ 240 ng/dL determined within 2 months prior to enrollment&#xD;
&#xD;
          -  At least 4 weeks must have elapsed from major surgery&#xD;
&#xD;
          -  KPS ≥ 80%&#xD;
&#xD;
          -  Prostate size as determined on MRI to be &lt; 90 cc. Prostate size can be determined on&#xD;
             CT scan if MRI is not available.&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  IPSS ≤ 20&#xD;
&#xD;
          -  Patient must be available for follow-up. After 2 years of follow-up following&#xD;
             post-treatment biopsy, telephone-based follow-up will be acceptable&#xD;
&#xD;
          -  Laboratory test findings within 8 weeks of randomization:&#xD;
&#xD;
               -  Adequate hepatic function with serum bilirubin ≤ 1.5 times the upper&#xD;
                  institutional limits of normal (ULN), ALT and AST ≤ 2.5 x ULN. Patients with a&#xD;
                  history of Gilbert's syndrome may be enrolled if the total bilirubin is &lt; 3 mg/dL&#xD;
                  with a predominance of indirect bilirubin&#xD;
&#xD;
               -  Adequate renal function with serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               -  Adequate hematologic function with absolute neutrophil counts ≥ 1,500 cell/mm3&#xD;
                  and platelets ≥ 100,000 cells/mm3 and hemoglobin value ≥ 9 g/dL (Note: patients&#xD;
                  whose anemia has been corrected to a hemoglobin value ≥ 9 g/dL with blood&#xD;
                  transfusions are allowed)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CT or MRI evidence of metastatic disease to the bone.&#xD;
&#xD;
          -  Patients with one or more positive lymph nodes considered suspicious as determined by&#xD;
             clinical assessment on MRI or CT&#xD;
&#xD;
          -  Prior treatment for prostate cancer, including history of chemotherapy, hormonal&#xD;
             therapy within 30 days of enrollment or surgery for prostate cancer (except for prior&#xD;
             TURP or greenlight PVP which would be allowed)&#xD;
&#xD;
          -  History of another malignancy within the previous 3 years except for the following:&#xD;
             adequately treated basal cell or squamous cell skin cancer, superficial bladder&#xD;
             cancer, currently in complete remission, or any other cancer that has been in complete&#xD;
             remission for at least 3 years&#xD;
&#xD;
          -  Patients with Crohn's disease or ulcerative colitis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zelefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Alliance MCI</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Androgen Deprivation Therapy</keyword>
  <keyword>Ultra-Hypofractionated SBRT</keyword>
  <keyword>16-1686</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

